

# CDH Treatment and Outcomes: What we've learned.

David W. Kays, MD

Director Center for Congenital Diaphragmatic Hernia

Director Extracorporeal Life Support

Johns Hopkins All Children's Hospital




JOHNS HOPKINS

All Children's Hospital



# Background

- Trained in Pediatric Surgery at Columbia University
  - Credit Charlie Stolar
  - Credit Jen Wung
  - Credit Jay Wilson
  - Credit Kevin Lally
  - Thank Matt Harting and the CDH community for asking me to speak



# I have no disclosures

- >450 CDH patients
- 321 at University of Florida
  - 1992 - 2015
- > 140 patients at Johns Hopkins All Children's Hospital
  - 2016 - present




# Outline

- Describe our population
  - 101 consecutive CDH cases at JHACH
  - Describe them by risk stratifiers
    - > Anatomy, lung volumes, physiology, associated anomalies
- Describe the care paradigm
  - Foundational principles
  - Ventilation
  - **Focus on ECMO**
  - **Focus on Repair**

# Describe Outcomes

- Survival
- Time in hospital
- Outcomes
  - Neuro imaging outcomes (gross)
- Conclusions

# **This is the disease: Pulmonary Hypoplasia (highly severe)**




# CDH Referral Pattern



High volume Referral Center


High percentage of prenatally diagnosed and evaluated patients

Increased Severity





# Johns Hopkins All Children's St Petersburg, FL





# Lessons Learned, treatments refined

- >450 CDH patients
- 321 at University of Florida
  - 1992 - 2015
- > 140 patients at Johns Hopkins All Children's Hospital
  - 2016 - present



# Analogy: Golf



- Golf is a HARD game
- To succeed: ALL ASPECTS of your game need to be good
  - Drives
  - Long irons
  - Short irons
  - Chipping
  - Putting
  - Rescue
  
  - One bad shot can ruin any hole

# CDH care is hard.

To succeed at CDH care, it's not just one thing.  
There is no single "secret"

## 5 major lessons learned

- Lungs: the primary key to survival**
- Repair: the second key to survival**
- ECMO: Critical to save the worst**
  - Must do Better ECMO**
- Risk stratification: know your patient**
- Offer your best therapy to your sickest patients**
- Belief: they do have enough lung to survive**

# Detrimental Effects of Standard Medical Therapy in Congenital Diaphragmatic Hernia

David W. Kays, MD, Max B. Langham, Jr., MD, Daniel J. Ledbetter, MD, and James L. Talbert, MD

*From the Department of Surgery, Division of Pediatric Surgery, University of Florida, and The Shands Children's Hospital at the University of Florida, Gainesville, Florida*

---

## Hypothesis:

- Hyperventilation/alkalosis is harmful to CDH patients
- Elimination of this therapy will result in improved survival
- Prospective change in therapy in August, 1992

Annals of Surgery. 1999. 230(3) 340-351  
Kays, Langham, Ledbetter, and Talbert

# CDH: Treatment Strategy


- Light to moderate sedation (no paralysis)
- Conventional SIMV pressure-limited ventilation with rate set to patient comfort and clinical state
- Lowest pressure which provides adequate chest movement (usually 20 - 24 cm H<sub>2</sub>O)
- Hyperventilation and alkalosis are strictly avoided

# Indications for ECMO

- Inability to maintain and insure adequate oxygen delivery to the brain
  - Pre-ductal sats < 85%
  - NIRS < 50%
  - Despite optimal support



# Mean PIP over 120 hours




Mean +/- SEM

$p < 0.05$  at all  
time points

$p = 0.00001$

Time\*Era  
effect

# Mean PIP over 120 hours




Mean +/- SEM

$p < 0.05$  at all time points

$p = 0.00001$

Time\*Era effect

# Survival Curve by Era, All



Survival Graph  
 $p < 0.0001$


# CDH Treatment Fundamental #1

Must eliminate any iatrogenic lung injury:

The number of CDH patients that survive is all about how well we take care of their lungs

# CDH Treatment Fundamental #2

- (2) Repair the Hernia (CDH) (n=268)



# When to repair

- Avoided ECMO:
  - Follow clinical course. When improvement plateaus, repair
  - Day 4 – 7 (mean 118 (+/- 27) hrs)

# Early repair before ECMO vs Delay and arrive to ECMO unrepaired (w/ opportunity)

	ECMO 1 <sup>st</sup> n=20	Repair first n=22	P= (Mann-Whit)
<b>Survived</b>	<b>13 (65%)</b>	<b>21 (96%)</b>	<b>0.018</b>
Apgar-5	5.9	6.0	.610
CDH SG Surv	52.4	58.2	.364
1 <sup>st</sup> LHR	1.1	1.1	.791
LHR o/e	30.6	28.5	.868
pH-1	7.1	7.1	.319
PO2-1	46.1	46.9	.705
PCO2-1	85.8	77.1	.307
<b>Surv Eq 1</b>	<b>.79</b>	<b>.77</b>	<b>.537</b>
<b>ECMO risk-1</b>	<b>.81</b>	<b>.83</b>	<b>.811</b>
<b>ECMO risk-2</b>	<b>.77</b>	<b>.80</b>	<b>.734</b>
<b>Pred Surv w/o ECMO</b>	<b>.20</b>	<b>.16</b>	<b>.801</b>

# Pros and Cons of “Repair before ECMO”

- Pros
  - It works. ECMO runs are easier, cleaner, better.
  - Minimal risk of bleeding
  - New comfort going to ECMO.
  - **Everyone gets repaired.**
- Cons
  - Repair becomes time sensitive:
  - Still concern could increase risk of ECMO
  - BUT WHY ALL THIS EFFORT???



# In early 2016, we transitioned from early repair “BEFORE ECMO”, to early repair ON ECMO

- Repair next am
- Ave time to ECMO: 30 hrs (+/- 33)
- Ave time to Repair: 65 hrs (+/- 69)
- Next morning is most common time for repair after initiating ECMO

# Principle #3

## Do Better ECMO

- Decision making and timing
- Better Circuits
- Better anticoagulation
- Better concepts
  - Support and weaning


## Better ECMO:

- All VA. (VV doesn't unload RV nor PA's)
- Repair early on ECMO. 24 hours
- Better anticoagulation:
  - Bivalirudin


# Bivalirudin

- Direct thrombin inhibitor
- Clean
- Predictable
- Efficacy?
  - Bleeding vs clotting?
- Pharmacokinetics
  - 20% renal excretion
  - **80% proteolytic degradation**
    - ? Where ? (important)

# APTT



# Anticoagulant Properties (?)



# ECMO Pumps

- Roller vs Centrifugal?
- Below 10 kg, not all centrifugal are created equal

# Offer your best treatment to your sickest patients. Believe they can survive.

- What are the outcomes in "the worst" CDH patients?
  - (Buckets A&B)

J Pediatr Surg. 2015 Jun;50(6):893-7

[Kays DW, Islam S, Perkins JM, Larson SD, Taylor JA, Talbert](#)

JL




6.64 / >130 / 15



	GA	BW	Ap-1	Ap-5	Pred %	Side	pH-1	PCO2	PO2	ECMO	Surv	d/c-m	Resp d/c
1	28	1053	1	2	4	Left	6.59	> 100	16	No	No	*	*
2	39	2000	0	1	6	Left	6.75	> 100	41	Yes	Yes	3.2	100 cc NC
3	38	3200	1	2	23	Right	6.67	> 100	75	Yes	No	*	*
4	36	3939	1	2	38	Left	6.64	> 130	15	Yes	Yes	3.4	400 cc NC
5	35	2645	0	4	31	Left	6.75	106	59	Yes	No	*	*
6	37	2400	2	1	9	Left	6.76	> 100	41	Yes	Yes	2.9	100 cc NC
7	35	2040	1	4	21	Left	6.81	145	46	Yes	No	*	*
8	27	988	3	1	2	Left	6.8	> 100	8	No	No	*	*
9	37	2500	1	3	20	Left	6.88	> 100	33	Yes	Yes	3.7	300 cc NC
10	37	2212	1	3	16	Left	6.95	> 100	62	Yes	No	*	*
11	33	1250	3	4	11	Left	6.86	96	49	No	No	*	*
12	39	2450	1	1	9	Left	7.04	79	37	Yes	Yes	3.4	100 cc NC
13	34	2595	2	5	40	Left	6.85	> 130	37	Yes	No	*	*
14	35	1880	3	4	18	Left	6.93	> 100	21	Yes	Yes	3.6	100 cc NC
15	38	2750	1	2	17	Left	7.07	67	44	Yes	No	*	*
16	37	3590	0	4	52	Right	6.93	> 100	48	Yes	Yes	1.6	400 cc NC
17	38	3030	2	4	39	Right	6.88	> 100	33	Yes	Yes	4.2	100 cc NC





**Most Severe 10%: (N=172) Survival 8/17 = 47%.**

# Survival vs Time on ECMO




J American College of Surgeons, 2014  
Kays, Islam, Larson, Perkins, Talbert

# Association of risk factors with Duration




# 1<sup>st</sup> Run ECMO vs 2<sup>nd</sup> Run ECMO for CDH

## 1st Run ECMO



## 2<sup>nd</sup> Run ECMO



# What if we put it all together?

- Protect lungs
- Risk Stratify Repair timing
- Get Everyone Repaired
- Do Great ECMO
  - Good decision making
  - Minimize errors
- Believe they can Survive
- What If ?

# CDH Program @ JHACH



- 101 Consecutive patients
- Unselected. All-comers\*
  - \*2 patients seen at our program chose to deliver at their home hospital. Both FDIU
    - Bilateral CDH with 2% o/e TFLV
    - Trisomy 15 mosaic with hydrops

# Our Paradigm

- CDH is about lung hypoplasia
  - All treatment decisions are about gas exchange and about helping little lungs work as well as they can.
  - Pulmonary Hypertension is a secondary issue, and does not drive management

# Treatment Specifics

- Prenatally evaluation including
  - LHR, Echo, and MRI (o/e TFLV)
  - Counseling
- Inborn Delivery at 38 weeks or so
- Resuscitation in Delivery Room by CDH Team
  - CDH surgeon, CDH neonatologist, CDH RT, CDH nurses
  - (Roles meld and titles fade)
- Conventional ventilation,
  - PIP 25 or less
  - Pre-ductal sats most important
  - Nitric Oxide started for near ECMO level hypoxemia
    - Pre-ductal sats less than 85, PO2 less than 35
  - ECMO when unable to maintain pre-ductal sats at or near 80 - 85 despite optimization of support (brain protection)



# Treatment Paradigm

- Risk stratify repair timing to minimize risk of ECMO
- Delay repair for 4 – 6 days (as long as improving)
- If goes to ECMO, repair within 24 hrs
  - Pediatric specific centrifugal or rollerhead pump
  - Bivalirudin probably better than heparin
  - Do GREAT ECMO: good decisions, good supportive care, time
  - Develop exceptional surgical technique and expertise
- Focus on lung function and gas exchange
  - Pulmonary hypertension is the symptom, not the disease
- Believe they can survive
  - Minimize Errors
  - Learn from mistakes
  - Simplify care

# ECMO Management

- VA ECMO
- Pump:
  - Sorin Revolution at JHACH (3 patients then changed)
  - Pedi-Mag for all subsequent ECMO (14 cc prime)
- Anticoagulation
  - Changed to Bivalirudin (3/1/2016)

# ECMO Weaning

- Athletic Training Paradigm
  - Wean ECMO at a (slow) rate that allows the heart and pulmonary vasculature to develop work capacity over time.
  - All ECMO patients started on sildenafil at 0.8 mg/kg/d when start wean phase (to help stabilize pulm vasc)
  - All patients successfully weaned and none required a second ECMO run.

# Second Axis of Severity: CDH Groups (Buckets)



The full spectrum of CDH:

- Associated anomalies: **None**
- "Isolated CDH"**



The full spectrum of CDH

- Associated anomalies: **less severe, not life threatening**
- ie. Small to moderate VSD, partial renal obstruction
- less severe genetic defects





The full spectrum of CDH

- Associated anomalies: **severe to life-threatening**
- major chromosomal** (trisomy 13, 15, 18, others)
- major heart defects. (STAT 3 or higher?)**
  - single ventricle physiology (HLHS, pulm atresia-VSD)
- bilateral CDH
- major abd wall defect: Giant Omphalocele
- major CNS anomaly

# 101 Consecutive patients


- Bucket A
  - (Isolated)
  - 71
  - Full spectrum of disease
- Bucket B
  - Assoc. Anomalies
  - 20
  - Large VSD: 2
  - DiGeorge Syndrome
  - Neonatal Diabetes
  - Klinefelter
  - Obstructive Uropathy
  - Serious but non-lethal chromosomal abnormalities
- Bucket C
  - Severe Assoc
  - 10
  - Bilat CDH-2
    - TFLV 6% and 8%
  - Complex Card-4
    - Single vent
    - Pulm atresia/VSD
    - TA w/ IAA
    - TAPVR w/ Em. Syn
  - Giant Omph.-2
  - Massive hydrocephalus

# JHACH Patient Distribution



58 of 101 had TFLV o/e less than 30%. (58%)

### JHACH MRI TFLV observed to expected (All Buckets)




# 9 worst patients by 1 hour ABG

Patient	pH @ 1 hour	PCO2 @ 1 hours	PO2 2 1 hour
1	< 6.80	> 134	50
2	< 6.80	> 112	46
3	6.83	> 112	64
4	6.85	> 122	29
5	6.91	91	43
6	6.94	> 134	32
7	6.96	116	31
8	6.96	119	51
9	6.99	103	49



Figure 1: Distribution by Severity by Defect Size




<b>Risk Stratifier</b>	<b>All CDH (n=101) Mean (SD)</b>	<b>No ECMO (n=37) Mean (SD)</b>	<b>ECMO (n=66) Mean (SD)</b>
<b>APGAR 1 min</b>	3.35 (2)		
<b>APGAR 5min</b>	5.94 (2)		
<b>CDH SG Predicted Survival</b>	60.7 (21)		
<b>LHR</b>	1.06 (0.4)		
<b>o/e LHR</b>	36 (15)		
<b>MRI-1 TFLV o/e</b>	27 (13)		
<b>MRI-2 TFLV o/e</b>	24.5 (9)		
<b>PH</b>	7.07 (0.19)		
<b>PCO2</b>	91 (36)		
<b>PO2</b>	77 (101)		
<b>Lactate</b>	3.3 (3.65)		


<b>Risk Stratifier</b>	<b>All CDH (n=101) Mean (SD)</b>	<b>No ECMO (n=37) Mean (SD)</b>	<b>ECMO (n=66) Mean (SD)</b>
<b>APGAR 1 min</b>	3.35 (2)	4.8 (2)	
<b>APGAR 5min</b>	5.94 (2)	7.1 (1.7)	
<b>CDH SG Predicted Survival</b>	60.7 (21)	76.5 (12)	
<b>LHR</b>	1.06 (0.4)	1.36 (0.54)	
<b>o/e LHR</b>	36 (15)	47 (18)	
<b>MRI-1 TFLV o/e</b>	27 (13)	40.4 (12)	
<b>MRI-2 TFLV o/e</b>	24.5 (9)	28.8 (6.8)	
<b>PH</b>	7.07 (0.19)	7.24 (0.13)	
<b>PCO2</b>	91 (36)	61.5 (24)	
<b>PO2</b>	77 (101)	131 (146)	
<b>Lactate</b>	3.3 (3.65)	1.8 (0.8)	

<b>Risk Stratifier</b>	<b>All CDH (n=101) Mean (SD)</b>	<b>No ECMO (n=37) Mean (SD)</b>	<b>ECMO (n=66) Mean (SD)</b>
<b>APGAR 1 min</b>	3.35 (2)	4.8 (2)	2.5 (1.5)
<b>APGAR 5min</b>	5.94 (2)	7.1 (1.7)	5.2 (1.8)
<b>CDH SG Predicted Survival</b>	60.7 (21)	76.5 (12)	51.6 (19.8)
<b>LHR</b>	1.06 (0.4)	1.36 (0.54)	0.93 (0.28)
<b>o/e LHR</b>	36 (15)	47 (18)	31 (10)
<b>MRI-1 TFLV o/e</b>	27 (13)	40.4 (12)	22 (8)
<b>MRI-2 TFLV o/e</b>	24.5 (9)	28.8 (6.8)	23 (9)
<b>PH</b>	7.07 (0.19)	7.24 (0.13)	6.97 (0.14)
<b>PCO2</b>	91 (36)	61.5 (24)	108 (30)
<b>PO2</b>	77 (101)	131 (146)	45 (32)
<b>Lactate</b>	3.3 (3.65)	1.8 (0.8)	4.0 (4.2)


# ECMO Survival to D/C




## CDH-ECMO Anatomy




## Buckets



# JHACH CDH Survival



## JHACH MRI TFLV observed to expected (All Buckets)



# Time in Hospital

- No ECMO
- Extubation: 12.7 (+/- 6 days)
- Discharge: 1.5 mos (+/- 0.9)
- ECMO
- Extubation: 32 (+/- 33) days
- Discharge: 2.42 (+/- 2.2) mos

95/ 97 went home breathing spontaneously

2 tracheostomies, both from Bucket C



# What we've learned



- Focus on the lungs
- Repair the CDH
- Do exceptional ECMO
- Believe they can survive

# What we've learned

- Pulmonary hypoplasia in CDH needs not be lethal
- We currently have the tools necessary for exceptional outcomes.
- Survival in CDH without major associated anomalies can approach **100%**
- We can look prenatal patients in the eye and quote **95% predicted survival**

# CDH

- **Quantity of Survival**
  - Care of lungs
  
- **Quality of Survival**
  - Care of brain
  
- **(Another talk)**







# JOHNS HOPKINS

## All Children's Hospital



all we do. all for kids.™